The costs of personalised cancer treatment must be considered, according to a new report.
Personalised therapy uses genetic sequencing techniques to give doctors a specific record of the genetic information in a patient's tumour, meaning the treatment is more likely to be effective.
Co-author of the paper, published in the British Journal of Cancer, D. Ross Camidge said the technique has lead to major breakthroughs, particularly in the treatment of lung cancer and the healthcare community needs to find ways of making it more affordable.
"Some organisations may not view a new drug as cost effective even if it works amazingly well for the small percentage who are proven positive by the test," said his fellow author health economist Adam Atherly.
However, the report concluded that the only way to beat cancer was to move away from the current universal treatment approach and ensure that personalised medicine is available to everyone who is diagnosed with the disease.